Prinomastat
 | |
| Pharmacokinetic data | |
|---|---|
| Biological half-life | 1-5 hours[1] |
| Identifiers | |
| PubChem (CID) | 466151 |
| IUPHAR/BPS | 6505 |
| ChemSpider | 409762 |
| UNII |
10T6626FRK  |
| ChEMBL | CHEMBL75094 |
| Chemical and physical data | |
| Formula | C18H21N3O5S2 |
| Molar mass | 423.5 g/mol |
Prinomastat (AG-3340) is a matrix metalloprotease (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, and 14. Investigations have been carried out to determine whether the inhibition of these MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. Prinomastat underwent a Phase III trial to investigate its effectiveness against non-small cell lung cancer (nsclc), in combination with gemcitabine chemotherapy. However, it was discovered that Prinomastat did not improve the outcome of chemotherapy in advanced Non-Small-Cell Lung Cancer.[1][2]
References
- 1 2 Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA (February 2005). "Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer." (PDF). Journal of Clinical Oncology. 23 (4): 842–9. doi:10.1200/JCO.2005.03.170. PMID 15681529.
- ↑ Hande, KR; Collier, M; Paradiso, L; Stuart-Smith, J; Dixon, M; Clendeninn, N; Yeun, G; Alberti, D; Binger, K; Wilding, G (February 2004). "Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor." (PDF). Clinical Cancer Research. 10 (3): 909–15. doi:10.1158/1078-0432.CCR-0981-3. PMID 14871966.
This article is issued from Wikipedia - version of the 8/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.